Alan B. Hollingsworth, MD

Topic: BREAST IMAGING

Establishing a Histologic Basis for False-negative Mammograms (1993) Hollingsworth AB, Taylor LDH, Rhodes DC. American Journal of Surgery 166:643-647.

Impact: This original study was cited in the 50^th Anniversary Edition of the American Journal of Surgery as one of the most important oncology articles published by that journal in its past half-century. The article also marks the beginning of Dr. Hollingsworth’s career transition from breast surgery to specializing in early diagnosis, risk analysis, genetic testing, and screening.

Positive Predictive Value of the Breast Imaging Reporting and Data System (1999)

Lacquement MA, Mitchell DS, Hollingsworth AB. Journal of the American College of Surgeons 189:34-40.

Breast MRI Screening for High-risk Patients (2008)

Hollingsworth AB, Stough RG. Seminars in Breast Disease 11:67-75.

Breast MRI for Preoperative Locoregional Staging (2008)

Hollingsworth AB, Stough RG, O’Dell CA, Brekke CE. American Journal of Surgery 196:389-397.

Impact: This was the largest single institution study reported at the time, and the data served as 20% of the total experience in pre-op MRI published at the time that was used to establish NCCN guidelines.

Multicentric and Contralateral Invasive Tumors Identified with Pre-op MRI in Patients Newly Diagnosed with DCIS of the Breast (2012)

Hollingsworth AB, Stough RG. The Breast Journal 18:420-427.

Impact: the only study of its kind. With pre-op MRI being of limited benefit in DCIS when it comes to the index lesion, this large series (largest study of MRI in DCIS at the time) raised another issue entirely – how common do women have life-threatening cancer of the breast unrelated in location to the site where DCIS has been diagnosed? Answer: 3.5% of the time, with 2.0% being on the opposite side of planned treatment. Implications are disturbing, in that surgeons can treat non-life-threatening disease on one side, while life-threatening cancer on the opposite side goes undiagnosed/untreated…1 out of every 50 DCIS patients, or 1,200 women in the U.S. each year.

Diagnostic Performance of a Dedicated 1.5-T Breast MRI Imaging System (2012)

Hillman BH, Harms SE, Stevens G, Stough RG, Hollingsworth AB, Kozlowski KF, Moss LJ. Radiology 265:51-58.

Impact: Four U.S. sites using Aurora breast-dedicated SpiralRODEOMRI™ performed a collaborative study revealing sensitivity and specificity to be much better (essentially 90-90) than what the historical literature was reporting (often with the intent to criticize MRI) using other technologies. Importantly, an attempt to slight the benefit of MRI was included in the 2009 U.S. Preventive Services Task Force that addressed screening mammography primarily.

An Alternative Approach to Selecting Patients for High-risk Screening with MRI (2014)

Hollingsworth AB, Stough RG. The Breast Journal 20:192-197.

Impact: The largest single-institution report of MRI screening at the time (n = 1,643), in which a remarkable one-half of patients whose cancers were discovered by MRI alone (negative mammograms) did NOT qualify for their MRI based on current national guidelines. This is attributed to the inclusion of breast density as a factor in patient selection, as well as flaws in the current guidelines that focus on lifetime risks, instead of short-term risks and density.

Computer-aided Breast MR Image Feature Analysis for Prediction of Tumor Response to Chemotherapy (2015)

Aghaei F, Tan M, Hollingsworth AB, Qian W, Liu H, Zheng B. Medical Physics 42:6520-6528.

Applying a New Quantitative Global Breast MRI Feature Analysis Scheme to Assess Tumor Response to Chemotherapy (2016)

Aghaei F, Tan M, Hollingsworth AB, Zheng B. J Magn Reson Imaging 2016; 44:1099-1106.

Overestimating Overdiagnosis in Breast Cancer Screening: editorial (2017)

Hollingsworth AB. Cureus 2017; e-pub 1/09/17. doi:7759/cureus.966.

Topic: Basic Science Prevention & Treatment

Prohibitin: a New Biomarker for Breast Tumors (1997)

Dell ‘Orco RT, Jupe ER, Manjeshwar S, Liu XT, McClung JK, King R, Kern W, Hollingsworth AB. The Breast Journal 3:85-89.

Prevention of DMBA-induced Rat Mammary Carcinomas Comparing Leuprolide, Oophorectomy, and Tamoxifen (1998)

Hollingsworth AB, Lerner MR, Lightfoot SA, Wilkerson KB, Hanas JS, McCay PB, Brackett DJ. Breast Cancer Research and Treatment 47:63-70.

Expression of Peroxisome Proliferator Activated Receptor mRNA in Normal and Tumorigenic Rodent Mammary Glands (1998)

Gimble JM, Pighetti GM, Lerner MR, Wu X, Lightfoot SA, Brackett DJ, Darcy K, Hollingsworth AB. Biochemical and Biophysical Research Communications 253:813-817.

Prevention of Rat Mammary Carcinoma Utilizing Leuprolide as an Equivalent to Oophorectomy (1999)

Jett EA, Lerner MR, Lightfoot SA, Hanas JS, Brackett DJ, Hollingsworth AB. Breast Cancer Research and Treatment 1526:1-6.

Therapeutic Treatment of DMBA-induced Tumors with PPAR ligands (2001)

Pighetti GM, Novosad W, Nicholson C, Hitt DC, Hansens C, Hollingsworth AB, Lerner ML, Brackett DJ, Lightfoot SA, Gimble JM. Anticancer Research 21:825-829.

Topic: Risk Assessment

The Evolution of Breast Cancer Risk Assessment (2002)

Hollingsworth AB, Nall S, Dill D. J Okla State Med Assoc 95:639-644.

Current Comprehensive Assessment and Management of Women at Increased Risk for Breast Cancer (2004)

Hollingsworth AB, Singletary SE, Morrow M, Francescatti DS, O’Shaughnessy JA, Hartman AR, Haddad B, Schnabel FR, Vogel VG. American Journal of Surgery 187:349-362.

IMPACT: Dr. Hollingsworth served as lead author and editor for this consensus paper at the request of Victor G. Vogel, MD who is considered a top expert in the U.S. on risk modeling and interventions. The working group was convened by the Susan G. Komen Foundation to outline a strategy for risk assessment and management in light of the addition of ductal lavage and cytology to the armamentarium used in risk stratification. Although cytology has lost much of its favor due to the challenges in specimen acquisition, this working group was the first to suggest using breast MRI in high-risk patients, three years prior to the MRI guidelines introduced by the American Cancer Society in 2007.

Screening for Breast Cancer Risk in the Obstetric/Gynecological Setting: a Breast Surgeon’s Perspective (2008)

West JG, Hollingsworth AB. Expert Reviews in Obstetrics and Gynecology 3:59-63.

Risk Assessment, Screening and Prevention of Breast Cancer: a Look at Cost-Effectiveness (2010)

Lebovic GS, Hollingsworth AB, Feig S. The Breast 19:260-267.

IMPACT: At the time of this collaborative effort, Dr. Lebovic was the outgoing president of the American Society of Beast Disease and Dr. Feig was the president-elect. Dr. Lebovic’s expertise as a pioneer in oncoplastic breast surgery (Cooper Clinic, Dallas, TX) and Dr. Feig’s expertise as one of the pioneers of mammography in the U.S. (University of California, Irvine) were combined with risk analysis perspectives from Dr. Hollingsworth.

Prediction of breast cancer risk using a machine learning approach embedded with a locality preserving projection algorithm (2018)

Heidari M, Khuzani AZ, Hollingsworth AB, et al. Phys Med Biol 2018; 63(3):035020. doi: 10. 1088/1361-6560/aaa1ca.

Applying a new computer-aided detection scheme generated imaging marker to predict short-term breast cancer risk (2018)

Mirniaharikandehei S, Hollingsworth AB, Patel B, Heidari M, Liu H, Zheng B. Phys Med Biol 63 (2018) 105005 (9pp) doi.org/10.1088/1361-6560/aabefe

Topic: Blood Testing to Detect Early Breast Cancer

Potential Use of Biomarkers to Augment Clinical Decisions for the Early Detection of Breast Cancer (2014)

Hollingsworth AB, Reese DE. Oncology and Hematology Review 10:103-109.

Diagnostic and Prognostic microRNAs in Serum of Breast Cancer Patients Measured by Droplet Digital PCR (2015)

Mangolini A, Ferracin M, Zanzi MV, et al…Hollingsworth AB, Negrini M. Biomark Res 2015; Jun 6;3:12. doi: 10.1186/s40364-015-0037-0

(results from specimens and data sent to the University of Ferrara (Italy) from Mercy Women’s Center in OKC)

Absolute Quantification of Cell-Free microRNAs in Cancer Patients (2015)

Ferracin M, Lupini L, Salamon I, et al…Hollingsworth AB, Negrini M. Oncotarget 6:14545-14555.

(results from specimens and data sent to the University of Ferrara (Italy) from Mercy Women’s Center in OKC)

Integration of Serum Protein Biomarker and Tumor Associated Autoantibody Expression Data Increases the Ability of a Blood-based Proteomic Assay to Identify Breast Cancer (2016)

Henderson MC, Hollingsworth AB, Gordon K, Silver M, Mulpuri R, Letsios E, Reese D. PLoS ONE 2016; 11(8): e0157692. doi:10.137/journal.pone.0157692

Topic: Invited Editorials

Ductal Lavage: the Pith and the Pendulum (2003)

Hollingsworth AB. Breast Diseases: A Year Book™ Quarterly 14:113-115.

Conflicting Outcomes with Preoperative Breast MRI: Differences in Technology or Methodology? (2010)

Hollingsworth AB, Stough RG. Breast Diseases: A Year Book™ Quarterly 21:109-112.

Preoperative MRI: the Controversy Continues (2013)

Hollingsworth AB, Stough RG. Breast Diseases: A Year Book™ Quarterly 24:19-23.

“The Beginning of Wisdom is the Definition of Terms – Socrates” (2015)

Hollingsworth AB. The Breast Journal 21:119-120.

(addressing the various problematic definitions of “multicentricity” and “local recurrence.”)

Pre-op MRI: Barking up the Wrong Endpoints? (2015)

Hollingsworth AB, Stough RG. Breast Diseases: A Year Book™ Quarterly 2015; 26:19-25

Invited Commentary on: Is Invasion a Necessary Step for Metastases in Breast Cancer? Hollingsworth AB (2018).

In response to: Narod SA, Sopik V. Breast Cancer Research and Treatment 2018: 169:633-637.

Impact: A new theory of breast cancer biology was proposed in 2018 by Narod and Sopik in the prestigious journal, Breast Cancer Research and Treatment, with the implication that DCIS can metastasize, prompting a completely new paradigm in which screening for breast cancer would have little or no impact. Given an advance copy of the article, Dr. Hollingsworth was invited by Editor Marc Lippman, MD, to offer a critique of the theory.